View source for Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

[[Category:Article]]
[[Category:Covid19]]
{| class="infobox" width=200px
|class="publication"|'''Publication'''
|-
|Title || <ul>[https://www.nature.com/articles/s41421-020-0156-0 Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro]</ul>
|-
|Authors || 
* Jia Liu
* Ruiyuan Cao
* Mingyue Xu
* ...
* Manli Wang 
|-
|Journal || Cell Discovery
|-
|Date|| March 18, 2020
|-
|}

In vitro study demonstrating that hydroxychloroquine is effective in inhibiting SARS-CoV-2 infection by blocking the transport of SARS-CoV-2 from EEs to Els, which is a requirement to release the viral genome. Authors conclude that hydroxychloroquine’s in vitro effect of inhibiting viral replication in combination with its anti-inflammatory function makes the drug a good candidate for treatment of COVID-19.

== Major Issues ==

No major issues identified at this time.

== Minor Issues ==

No minor issues identified at this time.

== Impact ==

This study demonstrated in vitro efficacy of hydroxychloroquine in blocking a necessary step in viral replication of SARS-CoV-2.

== Article Revisions ==

None at this time.

== References ==

<references/>